Jan. 10, 2017
Allergan has announced that it has reached separate agreements to partner with both Lysosomal Therapeutics and Assembly Biosciences for research and development. These announcements were released at the J.P. Morgan Healthcare Conference 2017.
Partnering with Lysosomal Therapeutics bolsters the pipeline of Allergan for neurodegenerative diseases. The deal also provides Allergan an option to buy the newly minted biotech start-up following a Phase 1b study for its lead product LTI-291. Lysosomal Therapeutics, the Cambridge, MA-based biotech focuses on Parkinson’s disease and could add a new string to Allergan’s well-established CNS bow should the big biopharma pursue an acquisition. However, the financial details were not disclosed.
The Assembly Biosciences deal hands Allergan worldwide rights to four preclinical bug-based programs in ulcerative colitis, irritable bowel syndrome (IBS), and Crohn’s disease in return for a payment of $50 million up front, along with development and commercial milestone payments, and tiered royalties. It is expected that the deal will close in the first quarter of 2017.
Allergan’s Chief Research & Development Officer David Nicholson said: “Parkinson’s disease is an area of medicine where significant unmet need exists, particularly in the development and potential breakthrough of disease-modifying treatments for the more than 2 million people suffering with Parkinson’s today.”
“The microbiome — the microbial populations that colonize the human body — is rapidly gaining prominence in numerous fields of research relevant to Allergan’s key areas of focus, including GI disorders,” Nicholson said in a separate statement.